Our top pick for
Savara Inc is a biotechnology business based in the US. Savara shares (SVRA) are listed on the NASDAQ and all prices are listed in US Dollars. Savara employs 36 staff and has a trailing 12-month revenue of around USD$256,000.
|Latest market close||USD$1.45|
|52-week range||USD$0.995 - USD$4.55|
|50-day moving average||USD$1.1529|
|200-day moving average||USD$1.7384|
|Wall St. target price||USD$3.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.577|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||N/A|
|1 month (2020-12-15)||N/A|
|3 months (2020-10-15)||N/A|
|6 months (2020-07-15)||N/A|
|1 year (2020-01-15)||N/A|
|2 years (2019-01-15)||N/A|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-22.44%|
|Return on equity TTM||-73.7%|
|Market capitalisation||USD$71.7 million|
TTM: trailing 12 months
There are currently 945,160 Savara shares held short by investors – that's known as Savara's "short interest". This figure is 3.8% down from 982,974 last month.
There are a few different ways that this level of interest in shorting Savara shares can be evaluated.
Savara's "short interest ratio" (SIR) is the quantity of Savara shares currently shorted divided by the average quantity of Savara shares traded daily (recently around 144963.19018405). Savara's SIR currently stands at 6.52. In other words for every 100,000 Savara shares traded daily on the market, roughly 6520 shares are currently held short.
However Savara's short interest can also be evaluated against the total number of Savara shares, or, against the total number of tradable Savara shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Savara's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Savara shares in existence, roughly 20 shares are currently held short) or 0.0158% of the tradable shares (for every 100,000 tradable Savara shares, roughly 16 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Savara.
Find out more about how you can short Savara stock.
We're not expecting Savara to pay a dividend over the next 12 months.
Savara's shares were split on 28 April 2017. This wouldn't directly have changed the overall worth of your Savara shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Savara shares which in turn could have impacted Savara's share price.
Over the last 12 months, Savara's shares have ranged in value from as little as $0.995 up to $4.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Savara's is 1.0701. This would suggest that Savara's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; Phase IIa development stage for treating nontuberculous mycobacterial (NTM) lung infection; and in Phase IIa development stage for the treatment of NTM lung infection in people living with cystic fibrosis. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.